Shares of Biomerica Inc. (BMRA) are soaring over 25% in pre-market today, after the company announced signing of two separate definitive license agreements with Mount Sinai's Icahn School of Medicine in New York to license technologies pertaining to a laboratory version serological test for SARS-CoV-2 virus infection which have been developed at Mount Sinai.
from RTT - Before the Bell https://ift.tt/2R4sPwt
via IFTTT
No comments:
Post a Comment